ArticleFrontiers in immunology2025
Development and validation of predictive models for meige syndrome patients based on oxidative stress markers.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Meige syndrome (MS) is a complex neurological disorder with unclear etiology. Accurate prediction of MS risk is essential for facilitating early diagnosis. This study aimed to develop and validate a nomogram for predicting the risk of MS based on oxidative stress markers. Methods: This retrospective, cross-sectional study included 424 patients with MS and 848 age- and sex-matched healthy controls, with data collected from January 2022 to December 2023. Clinical and laboratory data were extracted from electronic medical records. The MS patients and healthy controls were randomly allocated to the training and validation sets at a 7:3 ratio using random stratified sampling. A nomogram was developed using a multivariate logistic regression model based on data from the training set. Model performance was validated through fivefold cross-validation, receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA). Results: Univariate and multivariate logistic regression analyses identified albumin, gamma-glutamyl transferase (GGT), total bilirubin (TBIL), and the urea nitrogen-to-creatinine ratio as independent predictors of MS. A nomogram was constructed based on these four variables. The cross-validation confirmed the model's reliability. The model demonstrated high predictive accuracy, with an area under the curve (AUC) of 0.930 for the training set and 0.914 for the validation set. The calibration curve and DCA results indicate that the model has strong consistency and significant potential for clinical application. Conclusions: This study developed a nomogram based on four risk predictors, GGT, TBIL, albumin, and the urea nitrogen-to-creatinine ratio, to forecast the risk of MS and enhance the accuracy of MS risk prediction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.